stockportfolio.pro
Vertex Pharmaceuticals Incorporated (VRTX)
Healthcare · Biotechnology · NasdaqGS
Vertex Pharmaceuticals Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.70B | $2.49B | $3.05B | $4.16B | $6.21B | $7.57B | $8.93B | $9.87B | $11.02B | $12.00B |
| Gross profit | $1.49B | $2.21B | $2.64B | $3.62B | $5.47B | $6.67B | $7.85B | $8.61B | $9.49B | $10.35B |
| Net income | $-112.05M | $263.48M | $2.10B | $1.18B | $2.71B | $2.34B | $3.32B | $3.62B | $-535.60M | $3.95B |
| Net margin | -6.6% | 10.6% | 68.8% | 28.3% | 43.7% | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% |
Source: Vertex Pharmaceuticals Incorporated SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into VRTX stock?
At today's market cap of $113.14B, Vertex Pharmaceuticals Incorporated is priced for free-cash-flow growth of about 15.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $3.19B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 1.3%/yr over the last five fiscal years and revenue 14.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Vertex Pharmaceuticals Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VRTX in your portfolio →
Vertex Pharmaceuticals Incorporated financial history by metric
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Incorporated — frequently asked questions
What is Vertex Pharmaceuticals Incorporated's revenue?
Vertex Pharmaceuticals Incorporated (VRTX) reported revenue of $12.00B for fiscal year 2025, up 8.9% from the prior year, according to its SEC filings.
Is Vertex Pharmaceuticals Incorporated profitable?
Yes. VRTX earned net income of $3.95B in fiscal 2025, a net margin of 32.9%.
What is VRTX's P/E ratio?
Vertex Pharmaceuticals Incorporated trades at a price-to-earnings ratio of about 26.5 based on the latest data in our nightly-refreshed cache.
How fast is Vertex Pharmaceuticals Incorporated growing?
VRTX's revenue grew at roughly 14.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Vertex Pharmaceuticals Incorporated have?
As of fiscal year 2025, VRTX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Vertex Pharmaceuticals Incorporated's gross margin?
VRTX's gross margin was 86.2% in fiscal 2025 — gross profit of $10.35B on revenue of $12.00B.
What is Vertex Pharmaceuticals Incorporated's market cap?
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalization of about $113.14B, based on the latest data in our nightly-refreshed cache.
When does Vertex Pharmaceuticals Incorporated's fiscal year end?
VRTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into VRTX stock?
At today's market cap of $113.14B, Vertex Pharmaceuticals Incorporated is priced for free-cash-flow growth of about 15.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $3.19B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 1.3%/yr over the last five fiscal years and revenue 14.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Vertex Pharmaceuticals Incorporated's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.